BLA 761178 · Biogen INC
Aduhelm
Aducanumab-Avwa · Injection
NovelAccelerated approvalPriority reviewCDER novel approval, Jun 7, 2021: To treat Alzheimer's disease
Last checked: Nov 20, 2026Latest source record: Mar 15, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Jun 7, 2021
Approved uses
2
Original approval plus efficacy supplements
Registered trials
13
5 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To treat Alzheimer's disease
Therapeutic areas: Neurology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 8, 2023 Supplement 7 · Efficacy LetterLabel
- Jun 7, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalLabelLetterReview
2 products under this application
- ADUHELM · ADUCANUMAB-AVWA 170MG/1.7ML (100MG/ML) · INJECTABLE, INJECTION · Prescription
- ADUHELM · ADUCANUMAB-AVWA 300MG/3ML (100MG/ML) · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Aducanumab" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205Pivotal-lookingTerminated
BiogenBiogen (BIIB)
NCT04241068 · 1,696 participants · Start Mar 2, 2020 · Primary completion Jul 22, 2024
Drug: Aducanumab · For: Alzheimer's Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Sun City, Arizona · 297 sites in all
- 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's DiseasePivotal-lookingTerminated
BiogenBiogen (BIIB)
NCT02477800 · 1,653 participants · Start Aug 13, 2015 · Primary completion Aug 8, 2019
Drug: Aducanumab (BIIB037); Aducanumab (BIIB037) and 1 more · For: Alzheimer's Disease
Sites: Phoenix, Arizona; Tucson, Arizona; Fullerton, California · 181 sites in all
- 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's DiseasePivotal-lookingTerminated
BiogenBiogen (BIIB)
NCT02484547 · 1,643 participants · Start Sep 15, 2015 · Primary completion Aug 5, 2019
Drug: Aducanumab (BIIB037); Aducanumab (BIIB037) and 1 more · For: Alzheimer's Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Sun City, Arizona · 180 sites in all
- A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's DiseasePivotal-lookingTerminated
BiogenBiogen (BIIB)
NCT05310071 · 1,027 participants · Start Jun 2, 2022 · Primary completion Aug 12, 2024
Drug: Aducanumab; Placebo · For: Alzheimer's Disease
Sites: Gilbert, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 265 sites in all
- Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's DiseasePivotal-lookingTerminated
BiogenBiogen (BIIB)
NCT01677572 · 197 participants · Start Oct 5, 2012 · Primary completion Jul 31, 2019
Drug: Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb); Placebo · For: Alzheimer's Disease
Sites: Tucson, Arizona; Laguna Hills, California; Lomita, California · 32 sites in all
- A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)Pivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT05108922 · 148 participants · Start Nov 16, 2021 · Primary completion Sep 9, 2022
Drug: Donanemab; Aducanumab · For: Mild Cognitive Impairment (MCI); Alzheimer Disease
Sites: Fullerton, California; Irvine, California; Sherman Oaks, California · 31 sites in all
- A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy VolunteersPivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT05216887 · 123 participants · Start Feb 1, 2022 · Primary completion Jul 27, 2022
Drug: Aducanumab · For: Healthy Volunteer
Sites: Anaheim, California; Miami, Florida; Springfield, Missouri
BiogenBiogen (BIIB)
NCT01397539 · 53 participants · Start Jun 2011 · Primary completion Aug 2013
Drug: BIIB037 · For: Alzheimer's Disease
Sites: Delray Beach, Florida; Orlando, Florida; Beachwood, Ohio
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Aduhelm (Aducanumab-Avwa) · HCPCS J0172
2024 spending
$76K
Beneficiaries
19
76 claims
Per beneficiary
$4,007
2024 ASP limit $5.98 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $603,241 |
| 2023 | $71,670 |
| 2024 | $76,130 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis.
Terao I, Kodama W · Ageing Res Rev 2024 · Comparative Study, Systematic Review
- Aducanumab for the treatment of Alzheimer's disease: a systematic review.
Rahman A, Hossen MA, Chowdhury MFI, et al. · Psychogeriatrics 2023 · Systematic Review
- Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.
Budd Haeberlein S, Aisen PS, Barkhof F, et al. · J Prev Alzheimers Dis 2022 · Clinical Trial, Phase III, Multicenter Study
- The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.
Wu W, Ji Y, Wang Z, et al. · Eur J Med Res 2023 · Meta-Analysis, Systematic Review
- Amyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review.
Filippi M, Cecchetti G, Spinelli EG, et al. · JAMA Neurol 2022 · Case Reports, Systematic Review
- A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer's disease.
Chhabra A, Solanki S, Saravanabawan P, et al. · Expert Opin Biol Ther 2024 · Systematic Review
Sponsor: Biogen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.